Telix Pharmaceuticals Limited

NasdaqGS:TLX Stock Report

Market Cap: US$3.8b

Telix Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Telix Pharmaceuticals has been growing earnings at an average annual rate of 59.5%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been growing at an average rate of 54.1% per year. Telix Pharmaceuticals's return on equity is 6.9%, and it has net margins of 3.8%.

Key information

59.52%

Earnings growth rate

60.76%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate54.06%
Return on equity6.87%
Net Margin3.76%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Seeking Alpha • Aug 24

Telix Pharmaceuticals: Execution Is The Name Of The Game Here

Summary Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain tumor imaging) and resubmission plans for TLX250-Px (kidney cancer imaging). TLX’s radiopharmaceutical pipeline advances with pivotal studies in prostate cancer diagnostics and therapeutics, supported by robust financials and a recent $600 million convertible bond raise. Despite ongoing litigation and an inquiry by the SEC, I maintain a cautious Buy, emphasizing FDA and legal risks but optimistic on operational momentum. Read the full article on Seeking Alpha
Seeking Alpha • Dec 26

Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO

Summary Telix Pharmaceuticals Limited, an Australian company, focuses on theranostic cancer treatments, combining diagnostics and targeted therapy, with a diverse pipeline and commercial products. Their key commercial product, Illuccix, a prostate cancer imaging agent, has generated over $600 million in U.S. sales since April 2022. TLX591, their lead therapeutic candidate for prostate cancer, shows promising efficacy but has significant side effects; other pipeline candidates are in various trial stages. Despite financial stability and scientific progress, risks include scarce data and low trading volume due to TLX being a foreign issuer. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Telix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:TLX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2689133203213
31 Mar 2684713198192
31 Dec 25804-7193171
30 Sep 257362180163
30 Jun 2566712168154
31 Mar 2560321155145
31 Dec 2451734136128
30 Sep 2446034121116
30 Jun 2442833110109
31 Mar 243762110095
01 Jan 2433348385
30 Sep 23276-147075
30 Jun 23238-326170
31 Mar 23167-526061
31 Dec 22109-715955
30 Sep 2260-715340
30 Jun 2220-825531
31 Mar 2214-754730
31 Dec 216-583425
30 Sep 215-502823
30 Jun 215-442421
31 Mar 214-392119
31 Dec 204-351918
30 Sep 203-291516
30 Jun 202-251315
31 Mar 202-201113
31 Dec 192-201115
30 Sep 192-16914
30 Jun 191-13914
31 Mar 191-12814
31 Dec 180-10613
30 Sep 180-9610
30 Jun 180-756
31 Mar 180-644
31 Dec 170-532
31 Dec 160000

Quality Earnings: TLX has a large one-off gain of $14.0M impacting its last 12 months of financial results to 30th June, 2026.

Growing Profit Margin: TLX's current net profit margins (3.8%) are higher than last year (1.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TLX has become profitable over the past 5 years, growing earnings by 59.5% per year.

Accelerating Growth: TLX's earnings growth over the past year (183.8%) exceeds its 5-year average (59.5% per year).

Earnings vs Industry: TLX earnings growth over the past year (183.8%) exceeded the Biotechs industry 64.6%.

Return on Equity

High ROE: TLX's Return on Equity (6.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 20:03
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Madeleine WilliamsCanaccord Genuity